JP2023553610A - 重症急性呼吸器症候群関連コロナウイルスを標的とする干渉ｒｎａｓ、及びｃｏｖｉｄ－１９を治療するためのそれらの使用 - Google Patents

重症急性呼吸器症候群関連コロナウイルスを標的とする干渉ｒｎａｓ、及びｃｏｖｉｄ－１９を治療するためのそれらの使用 Download PDF

Info

Publication number
JP2023553610A
JP2023553610A JP2023534695A JP2023534695A JP2023553610A JP 2023553610 A JP2023553610 A JP 2023553610A JP 2023534695 A JP2023534695 A JP 2023534695A JP 2023534695 A JP2023534695 A JP 2023534695A JP 2023553610 A JP2023553610 A JP 2023553610A
Authority
JP
Japan
Prior art keywords
seq
sars
cov
sirna
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553610A5 (https=
Inventor
チャン，イー－チュン
ヤン，チー－ファン
チェン，イー－フェン
ヤン，チャ－チュン
チョウ，ユエン－リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oneness Biotech Co Ltd
Original Assignee
Oneness Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oneness Biotech Co Ltd filed Critical Oneness Biotech Co Ltd
Publication of JP2023553610A publication Critical patent/JP2023553610A/ja
Publication of JP2023553610A5 publication Critical patent/JP2023553610A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023534695A 2020-12-03 2021-12-03 重症急性呼吸器症候群関連コロナウイルスを標的とする干渉ｒｎａｓ、及びｃｏｖｉｄ－１９を治療するためのそれらの使用 Pending JP2023553610A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/133565 2020-12-03
CN2020133565 2020-12-03
CNPCT/CN2021/121762 2021-09-29
CN2021121762 2021-09-29
PCT/CN2021/135476 WO2022117085A1 (en) 2020-12-03 2021-12-03 Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19

Publications (2)

Publication Number Publication Date
JP2023553610A true JP2023553610A (ja) 2023-12-25
JP2023553610A5 JP2023553610A5 (https=) 2024-12-11

Family

ID=81853844

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534695A Pending JP2023553610A (ja) 2020-12-03 2021-12-03 重症急性呼吸器症候群関連コロナウイルスを標的とする干渉ｒｎａｓ、及びｃｏｖｉｄ－１９を治療するためのそれらの使用

Country Status (8)

Country Link
US (1) US20240026362A1 (https=)
EP (1) EP4256055A4 (https=)
JP (1) JP2023553610A (https=)
KR (1) KR20230142701A (https=)
CN (1) CN116964202A (https=)
AU (1) AU2021390130A1 (https=)
IL (1) IL303367A (https=)
WO (1) WO2022117085A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919267B (zh) * 2024-01-24 2024-12-03 石河子大学 miR2911在制备抗猪繁殖与呼吸障碍综合症病毒的药物中的应用
CN118001297B (zh) * 2024-02-01 2025-01-28 中国人民解放军军事科学院军事医学研究院 一种治疗SARS-CoV-2及其变体感染的多功能组合物及其制备方法
CN118853668A (zh) * 2024-06-24 2024-10-29 中山大学 一种靶向SARS-CoV-2的siRNA自组装纳米颗粒及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083430A2 (en) * 2003-03-21 2004-09-30 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
CN1590545A (zh) * 2003-06-04 2005-03-09 杭州新瑞佳生物医药技术开发有限公司 攻击SARS病毒mRNA分子的小干扰核糖核酸分子（SiRNA）及应用
WO2021183887A1 (en) * 2020-03-13 2021-09-16 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for viral genome targeting
WO2021195307A1 (en) * 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
WO2021207637A1 (en) * 2020-04-10 2021-10-14 Aligos Therapeutics, Inc. Short interfering nucleic acid (sina) molecules and uses thereof for coronavirus diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101113158A (zh) * 2006-12-18 2008-01-30 四川大学 干扰SARS病毒RdRp基因功能的siRNA
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
CN111778253B (zh) * 2020-04-03 2022-02-18 苏州吉玛基因股份有限公司 一种小干扰核酸及组合物和应用
CN111748557B (zh) * 2020-04-03 2022-03-11 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
CN111518809A (zh) * 2020-05-12 2020-08-11 杭州勇诚睿生物科技有限公司 干扰新冠病毒COVID-19基因表达的siRNA及其应用
RU2733361C1 (ru) * 2020-07-14 2020-10-01 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией
EP4359528A1 (en) * 2021-06-25 2024-05-01 Alpine Antiviral GmbH Sirna combinations targeting sars-cov-2 and/or host factor transcripts

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083430A2 (en) * 2003-03-21 2004-09-30 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
CN1590545A (zh) * 2003-06-04 2005-03-09 杭州新瑞佳生物医药技术开发有限公司 攻击SARS病毒mRNA分子的小干扰核糖核酸分子（SiRNA）及应用
WO2021183887A1 (en) * 2020-03-13 2021-09-16 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for viral genome targeting
WO2021195307A1 (en) * 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
JP2023519274A (ja) * 2020-03-26 2023-05-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド コロナウイルスｉＲＮＡ組成物およびその使用方法
WO2021207637A1 (en) * 2020-04-10 2021-10-14 Aligos Therapeutics, Inc. Short interfering nucleic acid (sina) molecules and uses thereof for coronavirus diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRECLINICA, vol. 2, no. 2, JPN6025051421, 2004, pages 135 - 142, ISSN: 0005753964 *

Also Published As

Publication number Publication date
IL303367A (en) 2023-08-01
CN116964202A (zh) 2023-10-27
EP4256055A4 (en) 2025-07-02
KR20230142701A (ko) 2023-10-11
WO2022117085A1 (en) 2022-06-09
AU2021390130A9 (en) 2025-04-03
US20240026362A1 (en) 2024-01-25
EP4256055A1 (en) 2023-10-11
AU2021390130A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Chang et al. A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
JP2023553610A (ja) 重症急性呼吸器症候群関連コロナウイルスを標的とする干渉ｒｎａｓ、及びｃｏｖｉｄ－１９を治療するためのそれらの使用
US20140287023A1 (en) 5'-triphosphate oligoribonucleotides
US20250101428A1 (en) Modification patterns for small interfering rna molecules with high stability and gene silencing activities
CN114729360A (zh) 降低病毒分子水平的方法
Beheshtirouy et al. Investigational antiviral drugs for the treatment of COVID-19 patients
US20170233742A1 (en) Compositions Comprising Small Interfering RNA Molecules for Prevention and Treatment of Ebola Virus Disease
TW202214296A (zh) 核酸脂質粒子疫苗
Joseph et al. The ineluctable role of ACE-2 receptors in SARS COV-2 infection and drug repurposing as a plausible SARS COV-2 therapy: a concise treatise
Cheng et al. Pharmacologic activation of the innate immune system to prevent respiratory viral infections
US20230242918A1 (en) Interferon- inducing oligonucleotide duplexes and methods of use
AU2024289222A1 (en) Il-1ra blockers for treatment and prevention of sepsis
US20240425853A1 (en) Modified small interfering rna molecules with reduced off-target effects
US20250367185A1 (en) Translesion synthesis polymerase inhibitors and uses thereof
US20240024405A1 (en) Compositions of caspase inhibitors and methods of use thereof
Reid The role of extracellular vesicle miRNA released in response to influenza A virus.
Zhang et al. Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2
Ge et al. Pulmonary delivery of small interfering RNA for novel therapeutics
WO2022049541A1 (en) Antiviral silencing rna molecules, chemically modified antiviral silencing rna molecules with enhanced cell penetrating abilities, pharmaceutical compositions comprising same and uses thereof for treatment of viral infections
WO2024175707A1 (en) A synthetic oligonucleotide for treating nidovirales infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313